MedPath

Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China

Conditions
Klebsiella Pneumoniae Infection
Interventions
Other: Carbapenem-Resistant Klebsiella pneumoniae
Registration Number
NCT03245632
Lead Sponsor
Sir Run Run Shaw Hospital
Brief Summary

Klebsiella pneumoniae is one of the most common pathogens causing nosocomial infection. Recently, the emergency of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) had cause the clinical therapy be very difficult. However, there is not much empirical data as to the prevalence, risk factors, characteristics, and the rationality of the current therapy for the CRKP infection. Thus, the study was aimed to investigate the epidemiology and risk factors, characteristics, and the rationality of the current therapy for the CRKP infection.

Detailed Description

All the patients with culture positive of Klebsiella pneumoniae were screened and reported to the the clinical doctors and confirmed by them. And the clinical characteristics of the patiens, such as baseline data, outcomes etc, were recorded. Finially, to find the prevalence, risk factors, characteristics, and the rationality of the current therapy for the CRKP infection

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
800
Inclusion Criteria
  • new confirmed noscomial infection of CRKP
Read More
Exclusion Criteria
  • Age<18, or >85 years old; Mixed infection of CRKP and other microbes
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Carbapenem-Resistant K. pneumoniaeCarbapenem-Resistant Klebsiella pneumoniaePatients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
Primary Outcome Measures
NameTimeMethod
CRKP infection7 days

Culture postitive results confirmed the infection of CRKP

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sir Run Run Shaw Hospital

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath